WIN Consortium collaborates with DECISION & STRATEGIE SANTE in media partnership
Posted: Thursday, May 17, 2018
The Worldwide Innovative Network (WIN) Consortium is proud to announce a media partnership with DECISION & STRATEGIE SANTE. They have come together to collaborate in the mutual promotion of their annual conferences.
The WIN Consortium will celebrate its 10th year Anniversary edition of the WIN Symposia at the WIN Symposium 2018 in Paris, France on 25-26 June 2018. “Global Implementation of Precision Oncology: WINning the War against Cancer” is this year’s theme for this celebratory event.
DECISION & STRATEGIE SANTE organizes meetings for the attention of health professionals on topical topics. Their annual congress entitled "The Encounters of Cancer Cancer" (RCFr 2018) is intended to present the main scientific, medical, technological and present and expected organizational structures in the many fields of modern cancerology. Their forthcoming conference will take place on 27-28 November 2018 at Chateauform 'Georges V – Paris, France.
The Worldwide Innovative Network (WIN) is a nonprofit organization dedicated to cancer research that organizes innovative clinical trials and organizes an annual symposium on advances in personalized medicine.
DECISION & STRATEGIE SANTE is a health communication company, leader in hospital and institutional markets. It brings together all the training, communication, publishing and event management specialized in health.
Diversity of Stakeholders - WIN Members
Studies with a global population
Sharing information to promote use of personalized, targeted cancer therapy: WIN Symposia
WIN was created to accelerate the pace and reduce the cost of translating novel cancer treatments to the bedside by developing and applying, through worldwide clinical trials and research projects, the most promising advances in genomic-based cancer research. WIN aims to initiate research projects each year in a global consortium guided by an independent scientific advisory board.
WIN now includes 40 institutional members. These stakeholders have come together from all parts of the world to address the challenge of increasing the efficacy of cancer diagnostics and therapeutics by understanding the genetics and biology of each individual’s tumor and accounting for genetic differences across diverse populations—from North and South America, Europe, Asia, and the Middle East.
Our goal is to significantly improve outcomes for patients around the globe. We aim to increase the number of patients worldwide that have access to innovative, global clinical trials in the area of genomic-based cancer therapeutics. Global diversity and inclusion of all stakeholders is WIN’s most important and differentiating asset.
Our members include leading academic, pharmaceutical, life science, not-for-profit, health IT, and healthpayer organizations.
WIN's first trial, WINTHER, is currently being carried out through a collaboration between six academic centers in five countries, with key support from Europe (EUFP7), Fondation ARC, Pfizer and other pharma companies.